Market News
3 min read | Updated on July 08, 2024, 15:06 IST
SUMMARY
The Emcure Pharma IPO subscription period was from July 3 to July 5. Shares of Emcure Pharma will be listed on the BSE and NSE, with a tentative listing date of July 10.
Emcure Pharma IPO allotment status expected on July 8: Steps to check share allocation on NSE, BSE and Link Intime
Emcure Pharma's IPO generated a lot of buzz ahead of its launch. The company’s initial public offering also garnered strong investor interest during the subscription period. On the final day of bidding on July 5, the public issue was booked nearly 68 times.
Investors placed bids for over 92.99 crore shares of Emcure Pharma compared to 1.37 crore shares on offer, leading to an overall subscription of 67.87 times.
The demand for the Emcure Pharma IPO was driven by the Qualified Institutional Buyer (QIB) category. The issue was subscribed 195.83 times in the QIB segment.
The pharmaceutical company’s issue was subscribed 48.32 times in the Non-Institutional Investor (NII) category, while under the retail category, the issue was subscribed 7.21 times.
The public issue was subscribed 8.81 times in the employees’ category as they placed bids for 9.59 lakh shares against the 1.08 lakh shares set aside for the category.
The IPO share allotment status is expected to be finalised on July 8. Shares will be credited to the demat accounts of successful bidders on July 9, while a refund will be initiated to unsuccessful bidders on the same day.
Shares of Emcure Pharma IPO will be listed on the BSE and NSE. The tentative listing date has been fixed as July 10.
Investors can check the share allotment status of Emcure Pharma IPO on BSE, NSE and registrar Link Intime India Pvt Ltd’s websites.
Emcure Pharmaceuticals aims to use the net proceeds from the IPO to repay or prepay outstanding borrowings and for general corporate purposes.
Emcure Pharmaceuticals Limited is a leading pharmaceutical company. The company is ranked 13th in domestic sales among pharmaceutical companies in India for the 12-month period ending September 2023 and 4th in market share in its covered markets for the same period. The company has a total of 13 manufacturing facilities in India.
About The Author
Next Story